Incremental prescription and drug costs during the years preceding diabetes diagnosis in primary care practices in Germany

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 7, 2006, Pages 348-355

  Icks, Andrea ^a,b   Haastert, B ^a   Giani, G ^a   Rathmann, W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Drug costs; Prescription; Primary care; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIURETIC AGENT;

ADULT; AGED; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

COST OF ILLNESS; DATABASES, FACTUAL; DIABETES MELLITUS; FAMILY PRACTICE; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PRIMARY HEALTH CARE;

EID: 33747608622     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924261     Document Type: Review

References (23)

1. American Diabetes Association (ADA). Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998; 21: 296-309
2. Barber JA, Thompson SG. Analysis and interpretation of cost data in randomized controlled trials: review of published studies. BMJ 1998; 317: 1195-2000
3. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck Study. Diabetes 2004; 53: 1782-1789
4. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999; 22: 1116-1124
5. D'Agostino RB, Hamman RF, Karter AJ, Mykkanen L, Wagenknech LE, Haffner SM. Insulin Resistance Atherosclerosis Study. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004; 27: 2234-2240
6. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Re-analysis of European epidemiological data. BMJ 1998; 317: 371-375
7. Dietlein G, Schröder-Bernhardi D. Use of the mediplus patient database in health care research. Int J Clin Pharmacol Therap 2002; 40: 130-133
8. Dukes MNG (ed). Drug Utilization Studies: Methods and Uses. European Series No 45, Copenhagen, Denmark, WHO Regional Office for Europe, 1993: 1-4
9. Federal Statistic Office (eds). Health Report for Germany. Metzler-Poeschel, Stuttgart, 1998: 379-410
10. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C for the conference participants. Definition of the metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-438
11. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes. Diabetes Care 2005; 28: 47-52
12. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. JAMA 1990; 263: 2893-2898
13. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134
14. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Int Med 2004; 164: 1066-1076
15. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990; 131: 443-453
16. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-559
17. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care 2000; 23: 1654-1659
18. OECD Health Data 2002. A software for the comparative analysis of 29 health systems. OECD electronic editions catalogue; 2002
19. Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care 1998; 21: 389-397
20. Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 2003; 46: 182-189
21. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108: 1546-1551
22. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997; 20: 1396-1402
23. The European Group for Study of Insulin Resistance. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376